Metabolic effect of two hormonal preparations in postmenopausal women

被引:7
作者
Bissonnette, F
LussierCacan, S
Fugere, P
Berube, S
机构
[1] UNIV MONTREAL,HOP ST LUC,DEPT OBSTET & GYNECOL,MONTREAL,PQ,CANADA
[2] INST RECH CLIN MONTREAL,MONTREAL,PQ H2W 1R7,CANADA
[3] BERLEX CANADA INC,LACHINE,PQ,CANADA
关键词
postmenopause; metabolic effect; hormone replacement therapy;
D O I
10.1016/S0378-5122(97)00042-X
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: To compare the metabolic and endocrinological effects of estradiol valerate/cyproterone acetate (EV/CPA) to a regimen of conjugated estrogens/medroxyprogesterone acetate (CE/MPA) in postmenopausal women. Methods: Lipid profile, endocrinological parameters, coagulation factors, renin and angiotensinogen were followed in postmenopausal women randomized to EV/CPA or CE/MPA during 12 cycles. Results: Following 12 cycles of treatment, total plasma cholesterol decreased more with EV/CPA than with CE/MPA. Low-density cholesterol decreased with EV/CPA while it increased with CE/MPA. High-density cholesterol remained fairly unchanged, and triglycerides increased significantly in both groups. Estradiol and estrone levels increased significantly more with EV/CPA than with CE/MPA while the sex-hormone-binding globulin increased more with CE/MPA. Follicle stimulating and luteinizing hormone levels also decreased significantly. Total testosterone and dihydroepiandrosterone sulfate remained stable. Total levothyroxine serum levels increased significantly, but thyroid stimulating hormone and triiodothyronine levels remained stable. Coagulation parameters also remained stable. Angiotensinogen increased, while plasma renin activity and blood pressure remained unchanged. Conclusion: It is concluded that both EV/CPA and CE/MPA produce favourable metabolic effects. A better lipid profile, compatible with decreased cardiovascular risk, is observed with the EV/CPA regimen. Higher circulating estrogen levels may explain in part this observation. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:275 / 284
页数:10
相关论文
共 27 条
[1]   A STUDY OF THYROID-FUNCTION IN THE PRE-MENOPAUSE AND POST-MENOPAUSE [J].
BOTTIGLIONI, F ;
DEALOYSIO, D ;
NICOLETTI, G ;
MAULONI, M ;
MANTUANO, R ;
CAPELLI, M .
MATURITAS, 1983, 5 (02) :105-114
[2]   LONG-TERM HORMONE REPLACEMENT TREATMENT IN MENOPAUSE - NEW CHOICES, OLD APPREHENSIONS, RECENT FINDINGS [J].
CAMPAGNOLI, C ;
LESCA, L ;
CANTAMESSA, C ;
PERIS, C .
MATURITAS, 1993, 18 (01) :21-46
[3]   BIOLOGIC EFFECTS OF TRANSDERMAL ESTRADIOL [J].
CHETKOWSKI, RJ ;
MELDRUM, DR ;
STEINGOLD, KA ;
RANDLE, D ;
LU, JK ;
EGGENA, P ;
HERSHMAN, JM ;
ALKJAERSIG, NK ;
FLETCHER, AP ;
JUDD, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (25) :1615-1620
[4]  
COLDITZ GA, 1992, HORMONE REPLACEMENT, P109
[5]  
CROOK D, 1992, HORMONE REPLACEMENT, P139
[6]   THE BENEFITS AND RISKS OF HORMONE REPLACEMENT THERAPY - AN EPIDEMIOLOGIC OVERVIEW [J].
HARLAP, S .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (06) :1986-1992
[7]   THE LONG-TERM EFFECT OF ORAL AND PERCUTANEOUS ESTRADIOL ON PLASMA-RENIN SUBSTRATE AND BLOOD-PRESSURE [J].
HASSAGER, C ;
RIIS, BJ ;
STROM, V ;
GUYENE, TT ;
CHRISTIANSEN, C .
CIRCULATION, 1987, 76 (04) :753-758
[8]   EFFECTS OF DIFFERENT PROGESTOGENS ON LIPOPROTEINS DURING POST-MENOPAUSAL REPLACEMENT THERAPY [J].
HIRVONEN, E ;
MALKONEN, M ;
MANNINEN, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (10) :560-563
[9]   CYPROTERONE-ACETATE, AN ALTERNATIVE PROGESTOGEN IN POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY - EFFECTS ON SERUM-LIPIDS AND LIPOPROTEINS [J].
JENSEN, J ;
RIIS, BJ ;
CHRISTIANSEN, C .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (02) :136-141
[10]   LONG-TERM AND WITHDRAWAL EFFECTS OF 2 DIFFERENT ESTROGEN-PROGESTOGEN COMBINATIONS ON LIPID AND LIPOPROTEIN PROFILES IN POST-MENOPAUSAL WOMEN [J].
JENSEN, J ;
RIIS, BJ ;
STROM, V ;
CHRISTIANSEN, C .
MATURITAS, 1989, 11 (02) :117-128